Venous thromboembolism constitutes a clinical spectrum encompassing deep venous thrombosis (DVT) and pulmonary embolism (PE). These are responsible for substantial morbidity and mortality. An exciting advance in this area of medicine involves the outpatient treatment of stable patients with DVT. This therapeutic approach, which has been facilitated by the advent of low-molecular-weight heparin (LMWH) preparations, is the focus of this supplement. The economic impact of DVT outpatient therapy is also addressed.
Deep Venous Thrombosis: Outpatient Therapy With Low-Molecular-Weight Heparin
Reimbursement of Enoxaparin for Outpatient Therapy
Reimbursement Strategies in an Outpatient-Based Disease Management Program for the Treatment of Deep Venous Thrombosis in an Integrated Health Care System
Outpatient Treatment of DVT in a 170,000-Member HMO
Reimbursement Considerations In the Treatment of Hypercholesterolemia: Economics and Implications for Medical Groups
The objective of this roundtable discussion is to review the impact of hypercholesterolemia on cardiovascular risk and public health. In addition, participants explore the clinical and pharmacoeconomic profiles of statins and consider their implications for medical group contracts with HMOs. Among the issues discussed: